Synergy between radiation of metastases and immunotherapy confirmed

Two clinical trials have now confirmed the abscopal or bystander effect in prostate cancer. These effects occur when cancer cells that are not directly treated are nonetheless killed.

Advances in the identification of patients who may respond well to particular types of immunotherapy

A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer.

Immunotherapy for men on active surveillance?

So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one:

Immunotherapy for the treatment of prostate cancer

The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line.

New trial of investigational immunotherapy in men on active surveillance

There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease.

Current thinking about immunotherapy in prostate cancer

A number of readers will probably be interested in reading at least part of an interview with Dr. Susan Slovin of the Memorial Sloan Kettering Cancer Center that has just been published on the CancerNetwork web site.

A new form of chemo-immunotherapy combination works very well — in mice!

Alas, our friends at The Daily Telegraph in the UK seem to have managed to hyperinflate some early scientific findings into an overnight cure for prostate cancer in general and  metastatic, castration-resistant prostate cancer in particular.

Radio-immunotherapy in the treatment of prostate cancer

Starting today, we have a new contributor to the content of The “New” Prostate Cancer InfoLink.

Combination immunotherapy for men with mCRPC: another new trial proposed

Late yesterday, Advaxis Immunotherapies announced the potential initiation of human trials of another new form of immunotherapy for the treatment of metastatic, castration-resistant prostate cancer (mCRPC).

The PrKT03 trial of radiation + immunotherapy for localized prostate cancer

Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer.

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC).

“Immunotherapy for prostate cancer: past, present, and future”

An article with the above title by Dr. Michael Glodé (a well-known medical oncologist at the University of Colorado in Denver) appears in the most recent issue of ASCO Connection.

Is cancer immunotherapy at a turning point?

Many readers may want to scan through this article by Gina Kolata in today’s issue of The New York Times that deals with the developing potential of immunotherapeutic agents in the management of cancer.

Better identification of potentially good responders to prostate cancer immunotherapy

A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others.

What’s next in prostate cancer immunotherapy?

Prostate stem cell antigen (PSCA) is a cell surface antigen found in normal human prostate tissue and over-expressed in men who have prostate cancer.